CDK4 and neoplasm: CDK4/6 inhibitors, suppress tumor proliferation by blocking the G1/S phase transition through competitive binding to the ATP domain of CDK4/6, thereby inhibiting phosphorylation of the retinoblastoma protein (Rb) and inducing irreversible G1 arrest.